BRISTOL MYERS SQUIBB CO (BMY) Form 10-Q — Jul 30, 2026
Bristol-Myers Squibb reported strong second-quarter 2026 results, with total revenues increasing 6% to $13.0 billion and GAAP EPS rising to $1.62 from $0.64 in the prior year. The growth was driven by a 22% increase in Eliquis sales and robust performance across the oncology portfolio, including Breyanzi (up 41%) and Reblozyl (up 29%), which offset the continued impact of generic erosion on Revlimid and Pomalyst. The company advanced its pipeline through the Hengrui collaboration, involving a $600 million upfront payment for 13 early-stage assets, and announced multiple regulatory milestones.
Key figures
- Eps
- 1.62
- Revenue
- 12973000000
- Net Income
- 3317000000
- Cash Position
- 8722000000
- Eps Six Months
- 2.93
- Repurchased Debt
- 1700000000
- Revenue Six Months
- 24462000000
- Net Income Six Months
- 5994000000
Price after filing
Close on the filing date to close N calendar days later (from $63.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.